Bio
Katarina Öhrling is a board certified clinical oncologist and a seasoned professional in the pharmaceutical/biotech industry, currently working in the Global Clinical Development Oncology team for AbbVie Inc. Dr. Öhrling has been instrumental in advancing innovative therapeutic solutions in immuno-oncology. Her expertise lies in the development and clinical implementation of new drugs in solid tumors spanning across diverse areas including translational research, early-phase and late-stage program evaluating innovative technology platforms such as oncolytic virus, bi-specific T-cell engagers, therapeutic cancer vaccines and ADCs.
At AbbVie Inc., Dr. Öhrling plays a pivotal role in leading strategic clinical development initiatives in oncology and overseeing global clinical trials. She has extensive experience in advancing investigational oncology assets into clinical trials as well as regulatory approvals. Dr. Öhrling's dedication to improving patient outcomes through advanced scientific research is reflected in her numerous contributions to peer-reviewed journals and her active participation in global oncology conferences.